Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection-Reference-Cited by-同舟云学术

Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection

Published:2021-03 Issue: Volume:153 Page:25-34
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Provencio Mariano,Majem Margarita,Guirado María,Massuti Bartomeu^ORCID,de las Peñas Ramón,Ortega Ana Laura^ORCID,Dómine Manuel,Marsé Raquel,Sala María Ángeles,Paredes Alfredo^ORCID,Morán Teresa^ORCID,Vázquez Sergio,Coves Juan,Larriba José Luis González,Sánchez José Miguel^ORCID,Vicente David,Farré Núria,Fornos Luis Fernández,Zapata Irma,Franco Fabio,Serna-Blasco Roberto^ORCID,Romero Atocha^ORCID,Isla Dolores^ORCID

Funder

Pierre Fabre

European Union’s Horizon 2020

Plan de Empleo Juvenil Comunidad de Madrid

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology;Hanna;J. Clin. Oncol.,2008

2. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients;Aupérin;Ann. Oncol.,2006

3. LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial;Faivre-Finn;Ann. Oncol.,2020